Forte Biosciences Discloses Nine Shareholder Demand Letters and $43M Advisor Fee in Tender Offer Amendment

summarizeSummary

Forte Biosciences' latest tender offer amendment reveals nine shareholder demand letters, a $43 million advisor fee, and extended financial projections used in the board's recommendation of argenx's $77 per share offer.

check_boxKey Events · M&A and Partnerships · FBRX

• Nine Shareholder Demand Letters

  Since August 6, 2026, the company received nine demand letters from purported shareholders alleging material omissions in the Schedule 14D-9 and demanding corrective disclosures. The company believes the claims are without merit.

• Guggenheim Fee Disclosed

  Guggenheim Securities will receive a cash transaction fee estimated at approximately $43 million upon deal consummation, with a $2.0 million opinion fee credited against it.

• Extended Financial Projections

  Projections now cover fiscal years 2026 through 2045, including estimated tax savings of approximately $153 million from net operating loss carryforwards in fiscal years 2032-2034.

• DCF Assumptions Detailed

  Guggenheim used a discount rate range of 11.75%-14.50% and a perpetual growth rate of negative 50.0% reflecting continued revenue decline after assumed loss of exclusivity for FB102 in 2043.

auto_awesomeAnalysis · FBRX · Life Sciences

This amendment to the tender offer recommendation adds material new details: nine shareholder demand letters alleging inadequate disclosure, a $43 million transaction fee for Guggenheim Securities, and expanded financial projections through 2045. The demand letters signal potential litigation risk, though no lawsuits have been filed yet. The fee disclosure quantifies the cost of the deal to shareholders. The projections and DCF assumptions provide deeper insight into the board's valuation analysis supporting the $77 per share offer.